Clinical Trial Update: A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

First-in-human proof-of-concept study of BEN2293 in mild to moderate atopic dermatitis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BEN2293

Snippet

Sponsor: BenevolentAI Bio | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: COMPLETED